In vitro activity of BAY v 3522, a new oral cephalosporin tested against Haemophilus influenzae and Branhamella catarrhalis.

The in vitro activity of BAY v 3522, a new orally absorbed cephalosporin, was assessed against 150 clinical isolates each of Haemophilus influenzae and Branhamella catarrhalis. The MIC90S for beta-lactamase-positive and -negative strains of H. influenzae were 8 and 2 micrograms/ml, respectively. For beta-lactamase-positive and -negative strains of B. catarrhalis, the BAY v 3522 MIC90S were 4 and 0.25 micrograms/ml, respectively. In general, BAY v 3522 was less active against H. influenzae than amoxicillin/clavulanic acid and cefixime, equivalent in activity to cefuroxime, and more active than cefaclor. BAY v 3522 had activity most similar to cefuroxime and cefaclor for B. catarrhalis but was less active than amoxicillin/clavulanic acid and cefixime.